Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment.

By Vaishnavi S, Gadde K, Alamy S, Zhang W, Connor K, Davidson JR.

Duke University Medical Center, Durham, NC 27710, USA.

Atypical depression, with features of hypersomnia, hyperphagia, anergia, and rejection sensitivity, is a common presentation of major depressive disorder. There are few available effective therapies for this disorder. We test modafinil, a novel wake-promoting agent, as monotherapy for atypical depression in a double-blind, placebo-controlled, relapse prevention trial after open-label treatment. We found that modafinil significantly improved atypical depression symptoms during 12 weeks of open-label treatment (mean +/- SD Hamilton Depression Scale (29-item version) score changed from 34 +/- 8.2 at baseline to 9.7 +/- 9.3, P < 0.0001), and that benefits were maintained alike in both the continuation and placebo arms during the double-blind treatment phase (P = 0.92). Modafinil was well tolerated and the drug was associated with significant weight loss compared with placebo (P = 0.01).

ProviglWeb does not sell Provigil or any other medication. We are not a medical site and cannot answer specific medical questions about your condition. Prescription medications such as Provgil should be taken only under the care of a doctor. Consult your doctor for advice about your situation.

Off-Label Provigil Use | News Stories | Provigil for Studying Hard | Sleep Resources | About Us